# Orencia (abatacept) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/abatacept

> The PDUFA target action date for Orencia (abatacept), sponsored by BRISTOL MYERS SQUIBB CO (BMY), is Dec 2026. Status: scheduled.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Orencia (abatacept) |
| Codes |  |
| Sponsor | BRISTOL MYERS SQUIBB CO (BMY) https://sec-api.dev/companies/bmy/catalysts |
| Indications | als and initiated a phase 2 trial |
| Modality | fusion_protein |
| FDA designations | priority review |

## Timeline

### December 15, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125118 SUPPL-240 (Efficacy): submission_status AP, submission_status_date 20211215, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product ORENCIA (ABATACEPT)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125118%22

### October 30, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125118 SUPPL-250 (Efficacy): submission_status AP, submission_status_date 20231030, review_priority STANDARD; sponsor_name BRISTOL MYERS SQUIBB; product ORENCIA (ABATACEPT)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125118%22

### Dec 2025: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: ALS and initiated a Phase 2 trial.
- First seen 2026-03-16, last confirmed 2026-03-16.
- SEC Form 10-K (accession 0001193125-26-107281): "Based on this POC data, we designed a well-powered and well-controlled study to demonstrate the safety and efficacy of COYA 302 (COYA 301 or low dose IL-2, plus an abatacept proposed biosimilar, licensed from Dr. Reddy's Laboratories ("DRL"), or DRL_AB) in patients with ALS and initiated a Phase 2 trial (ALSTARS) in December of 2025 after the acceptance of our IND application by the FDA." https://www.sec.gov/Archives/edgar/data/1835022/000119312526107281/coya-20251231.htm

### Dec 2026: PDUFA date

- Status: scheduled. Date confidence: month.
- First seen 2026-07-29, last confirmed 2026-07-29.
- Press release filed with the SEC (EX-99) (accession 0001575872-26-000536): "As we speak today, the goal date for abatacept is in mid-December 2026." https://www.sec.gov/Archives/edgar/data/1135951/000157587226000536/rdy0931_ex99-1.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/abatacept.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Orencia (abatacept) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/abatacept

```bibtex
@misc{secapidev_pdufa_abatacept_20261116,
  title        = {Orencia (abatacept) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/abatacept}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_abatacept_20261116","title":"Orencia (abatacept) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/abatacept","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
